BioSpace News Archive

Teva Canada Ltd. is recalling one lot of Pediatrix Acetaminophen Oral Solution after routine product testing found a higher than acceptable amount of acetaminophen in the affected lot (approximately 185mg/5mL rather than the approved and labelled 160mg/5mL).

R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has completed its previously announced acquisition of Acclara from Providence, one of the nation’s largest health systems.

Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company’s HFX™ 10 kHz Therapy for patients with chronic pain.

biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and Adjusted EBITDA to be slightly below prior guidance.

Stoke Therapeutics, Inc. announced that, effective on January 16, 2024, the company granted stock options to purchase an aggregate of 13,300 shares of common stock to 2 new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635.

Immatics N.V. announced the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share.

Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced the commencement of an underwritten public offering of its ordinary shares.

Aravive, Inc., announced that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended and suspend its public reporting obligations.

Sparta Biomedical, a privately held medical device company specializing in partial knee resurfacing, is set to present at the highly anticipated Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on February 7, 2024.